- Recommendation ID
- TA217/2
- Question
- Research is needed on the impact of treating Alzheimer’s disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
- Number
- TA217
- Date issued
- March 2011
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |